Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Biologics and Biosimilars Market Size is Likely to Upsurge USD 271.5 Billion Globally by 2028 | Analysis by Latest Trends, New Entrants, Economic Factors, Growing Demands, Opportunities, and Challenges | Extrapolate

Published

on

<!– Name:DistributionId Value:8782411 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1266639 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:615bed2b-3196-44d9-a4fd-1c93b6851d99 –>

Dubai, UAE, March 07, 2023 (GLOBE NEWSWIRE) — According to the latest research report released by Extrapolate, the global Biologics and Biosimilars Market size is estimated to grow to USD 271.5 Billion by 2028 from USD 191.6 Billion in 2021, registering a steady CAGR of 5.10% during the projection period.

The report argues that the market is now at an inflection point, thanks to the increasing number of FDA-approved biosimilars, the increasing acceptance of these products among healthcare providers and patients, and the growing number of companies investing in the development of biosimilars.

Download a FREE Sample of This Strategic Report: https://www.extrapolate.com/sample/healthcare-medical-devices-biotechnology/biologics-and-biosimilars-market-report/29620

The biologics and biosimilar market is further strengthened by developing more cost-effective and patient-friendly products, establishing more efficient regulatory pathways for approval and reimbursement and introducing new technologies like artificial intelligence and machine learning. “For instance, Talat Imran, CEO of Rani Therapeutics, recently said that the future of biologics lies in oral delivery through robotic capsules.” The report also highlights the potential for collaboration between biosimilar companies and the need for increased investment in research and development in the field.

Key Insights

  • By type, monoclonal antibodies dominated the global biologics and biosimilar market.
  • The tumor segment is expected to hold the largest market share by application.
  • Several favorable initiatives taken by governments across the globe in order to support the development of drugs are expected to drive market growth.
  • Key market players to expand their product line by launching new products to stay competitive.

Inquire Before Buying This Report: https://www.extrapolate.com/enquire/healthcare-medical-devices-biotechnology/biologics-and-biosimilars-market-report/29620

Competitive Landscape of Biologics and Biosimilars Market

The global biologics and biosimilar market is highly competitive, with key players employing several business strategies in order to maintain their market standing. The primary growth strategy implemented by leading businesses is to strengthen their product line by launching novel products.

For instance, on June 6, 2022, Amgen announced that the FDA had approved RIABNITM (rituximab-arrx), a biosimilar to Rituxan®, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who had an adverse reaction to one or more tumor necrosis factor (TNF) antagonist therapies. Granulomatosis with Polyangiitis (GPA), also known as Wegener’s Granulomatosis, Microscopic Polyangiitis (MPA), Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), and other diseases are already approved for treatment with RIABNI in adult patients. Moreover, in 2020, the company introduced AVSOLA®, a biosimilar to Remicade® (infliximab).

Key Players

  • Roche
  • Amgen
  • AbbVie
  • Sanofi-Aventis
  • Johnson & Johnson
  • Pfizer
  • Novo Nordisk
  • Eli Lilly
  • Novartis
  • Merck
  • 3sbio
  • Changchun High Tech
  • CP Guojian
  • Biotech
  • Gelgen
  • Innovent
  • Dong Bao
  • Ganlee
  • United Laboratories

Global Biologics and Biosimilars Market Segmentations:

The market for biologics and biosimilars is analyzed based on various factors such as types, applications, and regions. This detailed analysis helps identify potential challenges and opportunities in the market, allowing buyers to make informed decisions to improve their business strategies.

On the basis of Types:

  • Monoclonal Antibodies
  • Interferon
  • Erythropoietin
  • Insulin
  • Vaccines
  • Others

Purchase This Comprehensive Research Report for Valuable Market Insights: https://www.extrapolate.com/complete-checkout-buyal/29620

Monoclonal Antibodies Segment to Dominate Biologics and Biosimilars Market

In 2021, the monoclonal antibodies segment held a significant share of the market and was projected to maintain its dominance throughout the forecast period. This is due to several factors, including the broad range of applications for monoclonal antibodies in treating chronic diseases such as cancer, autoimmune disorders, and osteoporosis. Furthermore, these treatments are cost-effective, which is driving the segment’s growth.

Moreover, microbial systems are the primary source of recombinant proteins used in therapeutic procedures. Recombinant methods have facilitated the production of the most commercially available medications, thus promoting the growth of microbial systems.

On the basis of Applications, the Biologics and Biosimilars market is primarily split into:

  • Tumor
  • Diabetes
  • Cardiovascular
  • Hemophilia

Tumor Segment to Dominate Biologics and Biosimilars Market

Biologics and biosimilars have become increasingly important in tumor applications as they target specific cancer cells and improve patient outcomes. This has led to a strong demand for these drugs in cancer treatment. The rising demand for biologics and biosimilars for tumors can be attributed to several factors, such as increased incidences of cancer among people across the globe.

Regarding tumors, biologics and biosimilars have shown better efficacy and safety than traditional chemotherapy drugs. They are designed to target specific cells or proteins, which can reduce the risk of damaging healthy cells and causing side effects. Furthermore, many biologic drugs are approaching the end of their patent protection, which has paved the way for up opportunities for biosimilar manufacturers to develop and market similar products. This has created competition in the market, leading to lower prices for these drugs and increasing access to treatment options for cancer patients.

Browse the Complete Report Here: https://www.extrapolate.com/healthcare-medical-devices-biotechnology/biologics-and-biosimilars-market-report/29620

Geographic Segmentation:

  • North America (USA, Canada, Mexico)
  • Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
  • South America (Brazil, Argentina, Columbia, Rest of South America)
  • Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

North America to Dominate Biologics and Biosimilars Market Share

According to Extrapolate’s research analyst, North America is poised for significant growth during the forecast period. This growth is mainly attributed to several factors, including the region’s adoption of innovative R&D approaches and the increasing acceptance of biosimilars, which are less expensive substitutes for biologics with equivalent efficacy. The development of biologics is also fueling this growth.

In 2021, Europe led the market for biosimilars, valued at $7.53 billion, with a per capita consumption contribution of $17.8, significantly higher than the global average. The regional market is supported by several initiatives, including the European Medicines Agency’s (EMA) priority medicines (PRIME) program, which promotes the development of drugs addressing unmet medical needs. The rising geriatric population, high healthcare costs, and government funding for innovative research and development are further factors driving regional market growth.

Key Points from TOC:

1 Research Methodology and Statistical Scope
2 Biologics and Biosimilars Market Overview
3 Biologics and Biosimilars Market Competitive Landscape
4 Biologics and Biosimilars Industry Chain Analysis
5 The Development and Dynamics of the Biologics and Biosimilars Market
6 Biologics and Biosimilars Market Segmentation by Type
7 Biologics and Biosimilars Market Segmentation by Application
8 Biologics and Biosimilars Market Segmentation by Region
9 Key Companies Profiled
10 Biologics and Biosimilars Market Forecast by Region
11 Forecast Market by Type and by Application (2022-2028)
12 Conclusion and Key Findings

Browse Complete TOC: https://www.extrapolate.com/toc/healthcare-medical-devices-biotechnology/biologics-and-biosimilars-market-report/29620

About Us:

Extrapolate is a Global Market Research, Advisory, and Consulting firm that works closely with Industry experts from various industries to bring the latest and most accurate research reports.

In an era of breakneck change and a low tolerance for missed or misread opportunities, businesses need astute guidance to shape markets – not merely respond to them. Extrapolate helps clients develop market perspectives that drive success.


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

AI In Life Science Analytics Market worth $3.56 Bn by 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd.

Published

on

ai-in-life-science-analytics-market-worth-$356-bn-by-2031-–-exclusive-report-by-insightace-analytic-pvt-ltd.

JERSEY CITY, N.J., May 2, 2024 /PRNewswire/ — InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global AI In Life Science Analytics Market – By Component (Software, Hardware, Services), By Deployment (On-premise, Cloud), By Application (Research and Development, Sales and Marketing support, Supply chain analytics), By End-user (Medical Devices, Pharmaceutical, Biotechnology)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”

According to the latest research by InsightAce Analytic, the Global AI In Life Science Analytics Market is valued at US$ 1.63 Bn in 2023, and it is expected to reach US$ 3.56 Bn by 2031, with a CAGR of 10.39% during the forecast period of 2024-2031.
Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/2456 
AI in the context of life science analytics refers to the use of AI techniques and tools for the analysis of biological as well as environmental data. With the use of artificial intelligence (AI), life science analytics may make better use of complex healthcare, medical, and scientific information by applying high-level computational algorithms. 
The goal of life science analytics is to find useful patterns in massive amounts of medical, clinical, and biological data by applying various data analysis tools and techniques. Because of its superior computing and learning capabilities, AI is indispensable in improving life science analytics. The demand for more accurate and tailored techniques in healthcare and the life sciences, together with the rising availability of data, is projected to propel artificial intelligence in the life science analytics market to new heights as the discipline undergoes more development.
Pharmaceutical spending on complex diseases like cancer is on the rise, which is fueling the expansion of artificial intelligence in the life science analytics industry. However, implementing artificial intelligence (AI) solutions can be prohibitive for smaller organizations, making investing in the necessary technology and training difficult.
List of Significant Players in the AI In Life Science Analytics Market:
IndegeneLexalyticsDatabricksSAS Institute Inc.SisenseIQVIAIBMSorcero AtomwiseNuMediiAiCure LLCNuance CommunicationsAPIXIO, IncInsilico MedicineOther Market PlayersAI In Life Science Analytics Market Report Scope:
Report Attribute
Specifications
Market Size Value In 2023
USD 1.63 Bn
Revenue Forecast In 2031
USD 3.56 Bn
Growth Rate CAGR
CAGR of 10.39 % from 2024 to 2031
Quantitative Units
Representation of revenue in US$ Million and CAGR from 2024 to 2031
Historic Year
2019 to 2023
Forecast Year
2024-2031
Report Coverage
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered
By Component, Application, Deployment, And End-Use
Regional Scope
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Market Dynamics:
Drivers- 
The growing demand for AI in the life science analytics market is fueled by the exponential growth of data in the life sciences. Conventional methods of data analysis need to be revised in the face of the enormous amounts of biological, clinical, and healthcare data produced by genomics, proteomics, and electronic health records. Artificial intelligence (AI) has arisen as a game-changing solution because of its superior processing capabilities; it can handle and derive valuable insights from these immense and complicated datasets with ease. Incredible possibilities for pattern discovery, disease outcome prediction, and optimization of healthcare and life sciences research await in the mountains of data. Utilizing AI, researchers, healthcare experts, and pharmaceutical businesses can easily integrate and analyze various forms of data, which in turn allows them to uncover useful insights.
Challenges:
The prime challenge is a lack of awareness, a shortage of competent individuals, and a lack of norms and protocol because of lockdowns and isolation in emerging countries, which is predicted to slow the growth of AI in the life science analytics market. The low level of implementation of AI in several healthcare settings. There is no denying AI’s revolutionary promise in healthcare, yet smaller or less tech-savvy healthcare organizations face challenges when trying to integrate these new technologies. In these contexts, adoption is more gradual because of a lack of resources, including both financial commitment and trained staff. Implementing AI systems is complex, necessitating specialized training and infrastructure changes, which adds to the already existing difficulties. In addition, the health and life science sectors were helped by the COVID-19 epidemic. There was a dramatic uptick in the use of artificial intelligence (AI) for life science analytics as a response to the epidemic, which prompted the industry to speed up innovation in the face of such a dire threat. During the pandemic, markets worldwide grew because of AI-driven discoveries, not the months-long and similarly costly traditional methods of vaccine recognition.
Regional Trends:
The North American AI in life science analytics market is anticipated to record a large market share in terms of revenue. It is projected to grow at a high CAGR in the near future due to the high need for AI solutions in almost every field of life science. Artificial intelligence (AI) solutions for biotech, precision medicine, and drug development are in high demand in this country. Besides, Asia Pacific had a remarkable share in the market due to the fact that numerous research firms have ramped up their investments in artificial intelligence software and technology in an effort to boost operational efficiency.
Curious About This Latest Version Of The Report? Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/2456
Recent Developments:
In Feb 2024, Wipro and IBM extended their partnership in order to provide clients with new AI services and support. the Wipro enterprise ai-ready platform was developed by Wipro and IBM in the course of an extensive collaboration. The expanded collaboration merged the technological prowess and industry knowledge of Wipro with IBM’s pioneering hybrid cloud and AI developments. The objective was to develop collaborative solutions that facilitated the progress of integrating, enterprise-ready, dependable, and comprehensive artificial intelligence solutions.In Dec 2022, Quantori formed a partnership with Databricks to expedite data-driven advancements in the fields of life sciences and healthcare. Quantori created solutions using the Databricks Lakehouse Platform to offer immediate insights into real-world data to enhance patient outcomes for researchers and physicians.Segmentation of AI In Life Science Analytics Market-
By Component-
SoftwareHardwareServicesBy Deployment-
On-premiseCloudBy Application-
Research and DevelopmentSales and Marketing supportSupply chain analyticsOthersBy End-user-
Medical DevicesPharmaceuticalBiotechnologyBy Region-
North America-
The USCanadaMexicoEurope-
GermanyThe UKFranceItalySpainRest of EuropeAsia-Pacific-
ChinaJapanIndiaSouth KoreaSouth East AsiaRest of Asia PacificLatin America-
BrazilArgentinaRest of Latin America Middle East & Africa-
GCC CountriesSouth AfricaRest of the Middle East and AfricaFor More Customization @ https://www.insightaceanalytic.com/customisation/2456 
Why should buy this report:
To receive a comprehensive analysis of the prospects for global AI In Life Science Analytics marketTo receive industry overview and future trends of global AI In Life Science Analytics marketTo analyze the AI In Life Science Analytics market drivers and challengesTo get information on the AI In Life Science Analytics market size value (US$ Mn) forecast till 2031Major Investments, Mergers & Acquisition in global AI In Life Science Analytics market industryOther Related Reports Published by InsightAce Analytic:
Life Science Tools Market 
Big Data in Healthcare Market 
Digital Twins in Healthcare Market
eConsent In Healthcare Market
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact US:InsightAce Analytic Pvt. Ltd.Tel.: +1 551 226 6109Email: [email protected] Visit: www.insightaceanalytic.comFollow Us on LinkedIn @ bit.ly/2tBXsgS
Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/ai-in-life-science-analytics-market-worth-3-56-bn-by-2031—exclusive-report-by-insightace-analytic-pvt-ltd-302134305.html

Continue Reading

Artificial Intelligence

Fiix by Rockwell Automation Announces Industry-Leading GenAI Prescriptive Work Orders

Published

on

fiix-by-rockwell-automation-announces-industry-leading-genai-prescriptive-work-orders

Included in Fiix Asset Risk Predictor, Fiix Prescriptive Maintenance transforms asset health predictions into actionable work orders
BRUSSELS, May 2, 2024 /PRNewswire/ — Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, is excited to add cutting-edge, generative artificial intelligence (GenAI) prescriptive work orders to Fiix Asset Risk Predictor software, creating the first complete predictive and prescriptive maintenance solution to help manufacturers eliminate unplanned downtime.

Fiix Asset Risk Predictor’s powerful AI can be set up in as little as two weeks and starts predicting asset failures days in advance. With the addition of Fiix Prescriptive Maintenance, it now features GenAI capabilities that transform failure predictions into detailed, actionable work orders for maintenance teams.
Work orders are generated using asset data, completed work orders and trusted maintenance sources. Teams can then review and edit work orders, and instantly push them to any computerized maintenance management system (CMMS) or enterprise asset management (EAM) tool. All data is kept completely private and protected by the highest security standards.
“With Fiix Prescriptive Maintenance, you can turn asset data into the predictions and work orders you need to drastically reduce unplanned downtime, boost operational equipment effectiveness (OEE), and make better use of resources,” says Sandy D’Souza, senior director sales, Americas, Fiix by Rockwell Automation. “It also helps close the maintenance knowledge gap, ensuring everyone has access to detailed asset and work order information, whether they’ve just started their career or have decades of experience at a company.”
By bringing together AI-powered predictive maintenance and actionable GenAI work orders, Fiix Asset Risk Predictor ensures manufacturers see results in the fastest time possible.
Fiix Asset Risk Predictor, now including Fiix Prescriptive Maintenance, can be purchased and used independently from the Fiix CMMS or seamlessly integrated with it. It can also be integrated with any CMMS or EAM your company uses.
About Rockwell Automation 
Rockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 29,000 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise to life across industrial enterprises, visit www.rockwellautomation.com. 
Photo – https://mma.prnewswire.com/media/2403493/ARP_LP_Hero_Phase_2_2x.jpgLogo – https://mma.prnewswire.com/media/1981317/Rockwell_Automation_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/fiix-by-rockwell-automation-announces-industry-leading-genai-prescriptive-work-orders-302134253.html

Continue Reading

Artificial Intelligence

Breaking New Ground: Sentiance Introduces First Mobile Crash Detection for Motorcycles

Published

on

breaking-new-ground:-sentiance-introduces-first-mobile-crash-detection-for-motorcycles

ANTWERP, Belgium, May 2, 2024 /PRNewswire/ — Sentiance, a leader in road safety solutions, today announces a significant advancement in motorcycle safety with the expansion of its mobile Crash Detection technology. Originally developed for cars, this first-of-its-kind solution is now tailored specifically for motorcycles.

Built on state-of-the-art interpretive AI and machine learning models, Sentiance’s Crash Detection technology utilizes smartphone sensors and GPS data to analyze motion data in real-time. This enables the system to detect potential impacts with exceptional accuracy and reliability, addressing the unique dynamics of motorcycles. Unlike other systems, Sentiance’s technology operates directly on-device, ensuring a high level of privacy and data security.
“Today we see around 30% of all road crash deaths globally involving motorcycles, with countries like Thailand having an average of 5,000 motorcyclist deaths recorded annually. Ahead of the game, we’re not just enhancing safety features for those motorcycle riders, we are fundamentally transforming their safety landscape,” said Toon Vanparys, CEO of Sentiance. “This technology is not only a game-changer for individual safety but also addresses a significant need in markets where motorcycles are essential for daily transport and industries like food, grocery, and document delivery.”
This technology is especially crucial in regions like APAC, the Middle East, India, Africa, and South America, to transform road safety standards and make advanced safety tools easily accessible. Sentiance’s scalable and affordable technology ensures that even in cost-sensitive markets, safety, and privacy are not compromised.
By reducing accident response times and improving driving behaviors through data-driven insights, Sentiance’s mobile Crash Detection promises to reduce accident response times, saving lives and improving road conditions globally.
About Sentiance
Sentiance is the leader in motion insights. Our mission is to save lives every day and shape the future of road safety. Unlike telematics companies, we focus on the driver and not the vehicle because most accidents are caused by human error. 
With our revolutionary on-device AI technology, companies use insights from The Edge Platform to produce scalable, cost-efficient, and privacy-centric solutions for their customers.

View original content:https://www.prnewswire.co.uk/news-releases/breaking-new-ground-sentiance-introduces-first-mobile-crash-detection-for-motorcycles-302133343.html

Continue Reading

Trending